NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Akorn, Inc. (“Akorn” or the “Company”) (NASDAQ:AKRX) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/AKRX-Info-Request-Form-1848. There is no cost or obligation to you.
On February 26, 2018, Fresenius SE & Co. KGaA—which had been expected to close on an acquisition of Akorn—announced that it is conducting an investigation into alleged breaches of U.S. Food and Drug Administration “data integrity requirements relating to product development at Akorn.” Following this news, shares of Akorn were down more than 33% on intraday trading on February 27, 2018.
To learn more about the investigation of Akorn contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/AKRX-Info-Request-Form-1848.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.